1. Cell Cycle/DNA Damage
  2. Nucleoside Antimetabolite/Analog

LY2334737 

Cat. No.: HY-13672 Purity: 98.29%
Handling Instructions

LY2334737 is an orally available prodrug of gemcitabine which is a nucleoside analog used as chemotherapy.

For research use only. We do not sell to patients.

LY2334737 Chemical Structure

LY2334737 Chemical Structure

CAS No. : 892128-60-8

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 311 In-stock
Stock in the United States
Estimated Time of Arrival: December 31
5 mg USD 283 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
10 mg USD 432 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
50 mg USD 1026 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
100 mg USD 1596 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

LY2334737 is an orally available prodrug of gemcitabine which is a nucleoside analog used as chemotherapy. IC50 Value: Target: Nucleoside analog in vitro: Five cell lines that express CES2 responded to LY2334737treatment. LY2334737 was less cytotoxic to a SK-OV-3 CES2 knockdown than parental cells. The drug response of CES2-transfected HCT-116 cells correlated with CES2 expression level. Bystander studies showed statistically greater PC-3-GFP growth inhibition by LY2334737 when cells were cocultured with CES2 and not mock transfectants [1]. in vivo: Oral treatment of xenograft models with 3.2 mg/kg LY2334737 once a day for 21 days showed greater tumor growth inhibition of CES2 transfectant than the mock transfectant (P ≤ 0.001) [1]. The MTD was 40 mg LY2334737. Fatigue was the most frequent DLT for LY2334737monotherapy (4 patients) followed by elevated transaminase levels (2 patients), both observed at the 40- to 50-mg dose levels. Among the 10 patients in the combination arm, 2 had DLTs at the 40-mg dose level. These were fatigue and elevated liver enzyme levels [2]. Metronomic LY2334737 administration caused increased blood flow in luciferase-tagged LM2-4 tumor xenografts, and this effect, readily measured using contrast micro-ultrasound, coincided with a relative increase in tumor bioluminescence [3].

Clinical Trial
References
Molecular Weight

389.39

Formula

C₁₇H₂₅F₂N₃O₅

CAS No.

892128-60-8

SMILES

OC[[email protected]@H]1[[email protected]](C(F)(F)[[email protected]](N2C(N=C(C=C2)NC(C(CCC)CCC)=O)=O)O1)O

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
LY2334737
Cat. No.:
HY-13672
Quantity: